Reduction of primary AML by AbTCR and AbTCR-CSR T cells
Primary AML . | Reduction of CD33+ cells (%) . | HLA-A∗02:01 . | WT1 RMF/HLA-A2 complex expression . | CD33 expression . | ||||
---|---|---|---|---|---|---|---|---|
CSR only . | AbTCR no. 18 only . | AbTCR no. 34 only . | AbTCR-CSR no. 18 . | AbTCR-CSR no. 34 . | ||||
60D | None | 73 | 28 | 90 | 16 | + | + | 99% |
114B | None | 35 | 38 | 81 | 17 | + | + | 54% |
92C | None | 57 | 69 | 69 | 74 | + | + | 77% |
120B | None | 5.6 | None | None | 2.3 | − | − | 40% |
AML-14 | None | 41 | 55 | 74 | 55 | + | + | 99% |
Primary AML . | Reduction of CD33+ cells (%) . | HLA-A∗02:01 . | WT1 RMF/HLA-A2 complex expression . | CD33 expression . | ||||
---|---|---|---|---|---|---|---|---|
CSR only . | AbTCR no. 18 only . | AbTCR no. 34 only . | AbTCR-CSR no. 18 . | AbTCR-CSR no. 34 . | ||||
60D | None | 73 | 28 | 90 | 16 | + | + | 99% |
114B | None | 35 | 38 | 81 | 17 | + | + | 54% |
92C | None | 57 | 69 | 69 | 74 | + | + | 77% |
120B | None | 5.6 | None | None | 2.3 | − | − | 40% |
AML-14 | None | 41 | 55 | 74 | 55 | + | + | 99% |
Primary AML samples were labeled with either CFSE or far-red and coincubated with ESK2 AbTCR or AbTCR-CSR T cells at an effector-to-target ratio of 1:1, overnight. The cells were harvested and were stained with anti-CD33 mAb and analyzed by flow cytometry. The cells were gated on live cells and the same gates were applied to all groups. The percentage of CD33 and CFSE-positive (or far-red–positive) cells in the live cell gates were analyzed (as shown in supplemental Figure 6), and the percentage of total CD33+CFSE/far-red+ cells were calculated (including CD33low cells in AbTCR-CSR groups).
Percentage reduction of the AML cells by AbTCR, AbTCR-CSR T cells was calculated by comparison with mock T cells. HLA-A2, and CD33 expression were measured by flow cytometric analysis.
WT1 expression was assessed by ESK1 and ESK2 staining. AML-14 is a positive control AML cell line.
+, ≥1.5-fold increase over the isotype control staining for WT1 RMF/HLA-A2; +, ≥20 fold over isotype for HLA-A2 and CD33; and none, 0% to 1.5% reduction over mock T-cell groups.